On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Ipca Laboratories has increased 9.38% to Rs 2245.37 crore. Operating profit margin has jumped from 16.12% to 20.62%, leading to 39.95% rise in operating profit to Rs 463.08 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 29.29% to 21.46%. Purchase of finished goods cost rose from 5.59% to 8.38%. Employee cost decreased from 22.05% to 21.60%. Other expenses rose from 27.18% to 27.97%. Other income fell 10.42% to Rs 20.11 crore. PBIDT rose 36.75% to Rs 483.19 crore. Provision for interest fell 49.67% to Rs 16.81 crore. PBDT rose 45.78% to Rs 466.38 crore. Provision for depreciation fell 1.05% to Rs 98.46 crore. Profit before tax grew 66.91% to Rs 367.92 crore. Share of profit/loss was 41.21% higher at Rs -0.97 crore. Provision for tax was expense of Rs 90.59 crore, compared to Rs 66.24 crore. Effective tax rate was 24.69% compared to 23.06%. Minority interest decreased 31.37% to Rs 28.22 crore. Net profit attributable to owners of the company increased 37.95% to Rs 248.14 crore. Promoters’ stake was 44.72% as of 31 December 2024 ,compared to 46.29% as of 31 December 2023 .
For year-to-date (YTD) results analysis.
Net sales (including other operating income) of Ipca Laboratories has increased 18% to Rs 6692.9 crore. Operating profit margin has jumped from 17.62% to 19.38%, leading to 29.82% rise in operating profit to Rs 1,297.28 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 28.40% to 24.13%. Purchase of finished goods cost rose from 6.56% to 6.88%. Employee cost increased from 21.37% to 22.14%. Other expenses rose from 26.49% to 27.49%. Other income fell 36.72% to Rs 66.98 crore. PBIDT rose 23.45% to Rs 1364.26 crore. Provision for interest fell 41.76% to Rs 63.42 crore. PBDT rose 30.58% to Rs 1300.84 crore. Provision for depreciation rose 14.89% to Rs 297.7 crore. Profit before tax grew 36.09% to Rs 1,003.14 crore. Share of profit/loss was 89.38% higher at Rs -0.5 crore. Provision for tax was expense of Rs 281.39 crore, compared to Rs 239.77 crore. Effective tax rate was 28.06% compared to 31.49%.Minority interest increased 51.91% to Rs 51.39 crore. Net profit attributable to owners of the company increased 37.33% to Rs 669.86 crore. Promoters’ stake was 44.72% as of 31 December 2024 ,compared to 46.29% as of 31 December 2023 .
Full year results analysis.
Net sales (including other operating income) of Ipca Laboratories has increased 23.39% to Rs 7705.04 crore. Operating profit margin has jumped from 14.84% to 17.15%, leading to 42.56% rise in operating profit to Rs 1,321.16 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 27.81% to 28.28%. Purchase of finished goods cost fell from 8.09% to 6.25%. Employee cost increased from 20.96% to 21.80%. Other expenses fell from 28.05% to 26.80%. Other income fell 0.68% to Rs 124.77 crore. PBIDT rose 37.39% to Rs 1445.93 crore. Provision for interest rose 203.62% to Rs 138.27 crore. Loan funds declined from Rs 1,481.27 crore as of 31 March 2023 to Rs 1,438.36 crore as of 31 March 2024. Inventories rose to Rs 2,469.56 crore as of 31 March 2024 from Rs 1,743.37 crore as of 31 March 2023. Sundry debtors were higher at Rs 1,686.51 crore as of 31 March 2024 compared to Rs 989.02 crore as of 31 March 2023. Cash and bank balance declined from Rs 1,853.24 crore as of 31 March 2023 to Rs 296.84 crore as of 31 March 2024. Investments rose to Rs 862.01 crore as of 31 March 2024 from Rs 625.98 crore as of 31 March 2023 . PBDT rose 29.88% to Rs 1307.66 crore. Provision for depreciation rose 36.58% to Rs 357.24 crore. Fixed assets increased to Rs 4,805.84 crore as of 31 March 2024 from Rs 2,853.67 crore as of 31 March 2023. Intangible assets increased from Rs 38.14 crore to Rs 90.58 crore. Profit before tax grew 27.52% to Rs 950.42 crore. Share of profit/loss was 51.39% higher at Rs -6.29 crore. Provision for tax was expense of Rs 313.46 crore, compared to Rs 253.36 crore. Effective tax rate was 37.48% compared to 34.60%. Net profit attributable to owners of the company increased 16.13% to Rs 547.35 crore. Equity capital stood at Rs 25.37 crore as of 31 March 2024 to Rs 25.37 crore as of 31 March 2023. Per share face Value remained same at Rs 1.00. Promoters’ stake was 46.30% as of 31 March 2024 ,compared to 46.29% as of 31 March 2023 . Cash flow from operating activities increased to Rs 944.65 crore for year ended March 2024 from Rs 805.81 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 410.60 crore, compared to Rs 494.47 crore during the year ended March 2023. Other Highlights
In Q3 FY25,
Exports increased 6%, Indian formulations up 13% compared to Q3 FY24.
In 9M FY25,
Exports increased 3%, Indian formulations up 12% compared to 9M FY24.
In Q3 FY25, total
formulations revenue increased 10% YoY and API revenue up 12% on YoY basis.
In 9M FY25, total
formulations revenue increased 10% YoY and API revenue up 1% on YoY basis.
| Ipca Laboratories : Consolidated Results | | | Quarter ended | Year to Date | Year ended |
|---|
| Particulars | 202412 | 202312 | Var.(%) | 202412 | 202312 | Var.(%) | 202403 | 202303 | Var.(%) |
|---|
| Net Sales (including other operating income) | 2,245.37 | 2,052.85 | 9.38 | 6,692.90 | 5,672.01 | 18.00 | 7,705.04 | 6,244.32 | 23.39 | | OPM (%) | 20.62 | 16.12 | 451 bps | 19.38 | 17.62 | 177 bps | 17.15 | 14.84 | 230 bps | | OP | 463.08 | 330.88 | 39.95 | 1,297.28 | 999.26 | 29.82 | 1,321.16 | 926.77 | 42.56 | | Other Inc. | 20.11 | 22.45 | -10.42 | 66.98 | 105.85 | -36.72 | 124.77 | 125.62 | -0.68 | | PBIDT | 483.19 | 353.33 | 36.75 | 1,364.26 | 1,105.11 | 23.45 | 1,445.93 | 1,052.39 | 37.39 | | Interest | 16.81 | 33.40 | -49.67 | 63.42 | 108.90 | -41.76 | 138.27 | 45.54 | 203.62 | | PBDT | 466.38 | 319.93 | 45.78 | 1,300.84 | 996.21 | 30.58 | 1,307.66 | 1,006.85 | 29.88 | | Depreciation | 98.46 | 99.5 | -1.05 | 297.7 | 259.11 | 14.89 | 357.24 | 261.56 | 36.58 | | PBT | 367.92 | 220.43 | 66.91 | 1003.14 | 737.1 | 36.09 | 950.42 | 745.29 | 27.52 | | Share of Profit/(Loss) from Associates | -0.97 | -1.65 | 41.21 | -0.5 | -4.71 | 89.38 | -6.29 | -12.94 | 51.39 | | PBT before EO | 366.95 | 218.78 | 67.73 | 1002.64 | 732.39 | 36.90 | 944.13 | 732.35 | 28.92 | | EO Income | 0 | 68.46 | - | 0 | 28.97 | - | -107.75 | 0 | - | | PBT after EO | 366.95 | 287.24 | 27.75 | 1002.64 | 761.36 | 31.69 | 836.38 | 732.35 | 14.20 | | Taxation | 90.59 | 66.24 | 36.76 | 281.39 | 239.77 | 17.36 | 313.46 | 253.36 | 23.72 | | PAT | 276.36 | 221 | 25.05 | 721.25 | 521.59 | 38.28 | 522.92 | 478.99 | 9.17 | | Minority Interest (MI) | 28.22 | 41.12 | -31.37 | 51.39 | 33.83 | 51.91 | -24.43 | 7.67 | LP | | Net profit | 248.14 | 179.88 | 37.95 | 669.86 | 487.76 | 37.33 | 547.35 | 471.32 | 16.13 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 248.14 | 179.88 | 37.95 | 669.86 | 487.76 | 37.33 | 547.35 | 471.32 | 16.13 | | EPS (Rs)* | 9.78 | 5.39 | 81.31 | 26.40 | 18.49 | 42.78 | 24.36 | 18.58 | 31.15 | | | * EPS is on current equity of Rs 25.37 crore, Face value of Rs 1, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|